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Abstract
Background: Health economic evaluations of interventions in infectious disease are commonly based on the
predictions of ordinary differential equation (ODE) systems or Markov models (MMs). Standard MMs are static, whereas
ODE systems are usually dynamic and account for herd immunity which is crucial to prevent overestimation of
infection prevalence. Complex ODE systems including distributions on model parameters are computationally
intensive. Thus, mainly ODE-based models including fixed parameter values are presented in the literature. These do
not account for parameter uncertainty. As a consequence, probabilistic sensitivity analysis (PSA), a crucial component
of health economic evaluations, cannot be conducted straightforwardly.
Methods: We present a dynamic MM under a Bayesian framework. We extend a static MM by incorporating the force
of infection into the state allocation algorithm. The corresponding output is based on dynamic changes in prevalence
and thus accounts for herd immunity. In contrast to deterministic ODE-based models, PSA can be conducted
straightforwardly. We introduce a case study of a fictional sexually transmitted infection and compare our dynamic
Bayesian MM to a deterministic and a Bayesian ODE system. The models are calibrated to simulated time series data.
Results: By means of the case study, we show that our methodology produces outcome which is comparable to the
“gold standard” of the Bayesian ODE system.
Conclusions: In contrast to ODE systems in the literature, the dynamic MM includes distributions on all model
parameters at manageable computational effort (including calibration). The run time of the Bayesian ODE system is 15
times longer.
Keywords: Infectious disease, Herd immunity, Dynamic Markov model, Bayesian framework, Cost-effectiveness
analysis, Health economic evaluation, Probabilistic sensitivity analysis
Background
Vaccines, antibiotics and antivirals against infectious dis-
eases offer health benefits to society [1, 2] and have
been instrumental in the prevention and treatment of
conditions previously causing egregious burden to public
health. Examples include the extremely low prevalence
of syphillis, the control of human immunodeficiency
virus, the worldwide eradication of smallpox [3] and
the extremely low incidence of tetanus, diphteria and
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congenital rubella syndrome in the Western world [4].
However, despite being frequently successful from a clin-
ical point of view, vaccination programmes and antiretro-
virals are often costly to apply. As a pre-requisite to their
implementation, health interventions such as vaccines are
thus increasingly subject to cost-effectiveness analyses
(CEAs) [5, 6].
The National Institute for Health and Care Excellence
(NICE) is arguably the leading health technology assess-
ment agency in the world. In the UK, NICE is responsible
for providing guidance and advice on whether proposed
interventions should be publicly funded. NICE has devel-
oped a set of criteria and guidelines that drive the analytic
process of CEA [7]. Crucially, these involve the explicit
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necessity of assessing the impact of parameter uncer-
tainty on the decisionmaking outcome, a process typically
known as Probabilistic Sensitivity Analysis (PSA) [6, 8, 9].
In the UK, the appraisal of vaccines falls under the
remit of the Joint Committee for Vaccines and Immuni-
sations, an independent expert advisory committee to the
ministers and health departments. Since 2009, the Health
Protection Regulation obliges the Secretary of State to
ensure that recommendations for national vaccination
programmes are based on an assessment demonstrat-
ing cost-effectiveness [10]. However, there are currently
no vaccine-specific guidelines for developing clinical or
cost-effectiveness evidence.
One of the reasons for this circumstance is perhaps
the intrinsic complexity of infectious disease modelling,
which is typically performed through compartmental
models. These are highly complicated mathematical tools
capable of simulating the natural history of disease infec-
tion and progression. More specifically, in pathogens
transmissible among humans, these models need to
account for population dynamics and herd immunity
[11]. Herd immunity implies that due to lower infection
prevalence, the introduction of preventive and therapeu-
tic measures such as vaccination, quarantine, antivirals
and antibiotics induces a reduced risk of pathogen expo-
sure. Only dynamic models are able to prevent incorrect
predictions since they are suitable to incorporate these
effects [12–14].
Dynamic compartmental models are commonly fitted
by solving systems of Ordinary Differential Equations
(ODEs) in continuous time. While these deterministic
models usually deal with features such as herd immu-
nity (and thus are considered the “industry standard”
in infectious disease modelling), they are characterised
by a notable computational effort. One important con-
sequence is that, in most cases, epidemiological and
economic modelling for infectious disease performed by
means of ODEs is based on the inclusion of fixed, prede-
fined values on the model parameters. These fixed values
are usually informed through a point estimate. The joint
uncertainty in the parameters is then not considered;
these models result in outcome (e.g. on the number of
people in the states) which does not include distributions.
Therefore, PSA on the model outcome can only be con-
ducted in retrospect and not in a straightforward way.
An additional step using Latin Hypercube Sampling or
Monte Carlo sampling is necessary, as shown in [15–17]
and [18–20], respectively. Alternative methods that may
prove computationally efficient when estimated through
polynomial chaos expansions as shown in [21, 22] are pro-
vided by the Sobol and Fourier amplitude sensitivity test
(FAST) indices. These indices are based on ANOVA tech-
niques and thus estimate the total contribution of each
model parameter or a combination of parameters to the
variance of the model output [23, 24]. However, in con-
trast to a full PSA, uncertainty is not propagated through
the whole model.
The computational feasibility of PSA in retrospect is
limited in models which include a high number of states
and model parameters. In addition, in contrast to a
Bayesian approach, parameter uncertainty is not propa-
gated through the crucial model parts of pathogen trans-
mission and disease progression. The outcome based on
fixed parameter values can differ considerably from the
PSA outcome, and the two are in most cases not reported
in enough detail to identify possible inconsistencies (with
the exception of [19]). The results presented commonly
focus on uncertainty in the health economic rather than
the prevalence outcome of the models, and PSA results
on infection prevalence including the corresponding con-
fidence intervals are often not given [18, 20, 25]. This
approach is highly questionable, especially with respect
to consistency with validation targets. To ensure that the
model outcome on the number of people in the states and
infection prevalence is realistic, calibration to high quality
data based on large sample size is necessary. This is often
not conducted [25], or only conducted on the outcome
based on fixed parameter values [18]; the PSA outcome on
prevalence is usually not evaluated with respect to fitting
high quality data [19, 20, 26].
The more complex an ODE system especially with
respect to state space and number of model parameters,
the larger the effort on implementation and computation,
especially if each model parameter is assigned a suitable
distribution. This might be one of the reasons why the
International Society for Pharmacoeconomics and Out-
comes Research guideline for best modelling practice in
infectious disease suggests that PSA is not a fundamental
component of health economic assessment [12]. This rec-
ommendation is given in contrast with NICE and virtually
any other disease area. As a consequence, most economic
models for vaccines only consider deterministic sensitivity
analysis, which is based on selecting a grid of “plausi-
ble” values for a subset of model parameters in order
to assess the robustness of the decision-making process.
This approach is however not recommended in general,
as it fails to account for potential correlation among the
parameters [6, 9, 27].
In contrast to ODE-based models, systems of equations
can also be defined in discrete-time, which are termed
difference equation models [28]. An alternative compart-
mental specification is given by Markov models (MMs).
MMs are used to model progression over time across a
finite set of states. Since MMs are described by a stochas-
tic process, these are classified as stochastic models. This
is in contrast to ODE systems and difference equation
models, which belong to the class of deterministic models.
In a deterministic model, the same set of parameter values
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and initial conditions always results in the same output.
In contrast, a stochastic model produces different output
each time the model is run, accounting for randomness.
Apart from the model class, difference equation models
and discrete-time MMs are mathematically comparable.
Although MMs can also be computationally intensive,
it is generally feasible to implement even complex models
in a Bayesian framework or to use re-sampling methods
such as the bootstrap to characterise the uncertainty in
the model parameters. Perhaps for this reason, MMs are
a very popular tool in health economic evaluation. Never-
theless, a major limitation in infectious disease modelling
is that they are intrinsically static, i.e. they do not account
for population dynamics [29].
We introduce in this paper an extension to standard
MMs, which we term “dynamic Bayesian MM” to indi-
cate that we consider a stochastic model and use a
Bayesian framework to estimate its underlying param-
eters. We directly include the force of infection of
the pathogen, which automatically accounts for time-
dependent changes in prevalence and thus the effects of
herd immunity, into the state allocation algorithm of a
MM. In other words, the movement of susceptibles to the
state of infection is directly represented by the dynamic
force of infection. A direct inclusion of the force of infec-
tion into the state allocation algorithm of a difference
equation model [30], a MM [31, 32] or its direct consid-
eration in a model based on a stochastic process [33–35]
was presented previously by several authors. However, the
authors who present stochastic models do not conduct a
health economic evaluation. In the health economics lit-
erature, to the best of our knowledge, no approach of a
dynamic MM including a high number of states and suit-
able probability distributions on all model parameters is
presented.
Our dynamic Bayesian MM combines six advantages in
comparison to the few dynamic MMs presented in the
literature. Firstly, in contrast to our contribution, the com-
partmental models in the literature are only suitable to
include a low number of states due to computational lim-
itations and the majority consist of no more than four
states (apart from [30]). Our methodology is especially
suitable to incorporate an extensive number of states as
described elsewhere [36] for the application to human
papillomavirus (HPV) modelling. In our model on HPV,
36 states in females and 22 states in males are included to
account for all known HPV-induced diseases apart from
recurrent respiratory papillomatosis. In addition, statisti-
cians or health economic modellers can implement our
approach directly in the commonly used software R link-
ing to JAGS or WinBUGS; the corresponding run-time is
considerably fast, and therefore, it is not necessary to use
a compiled language such as C which is usually not widely
used in this field. The four remaining advantages are
given through the Bayesian framework, which i) is highly
flexible with its probabilistic nature since it considers mul-
tiple sources of prior information in terms of evidence
synthesis [37], ii) enables propagation of parameter uncer-
tainty through the infection transmission, progression and
economic evaluation process, iii) ensures that calibration
targets are met through a constant updating process of the
outcome on the numbers of people in the states directly in
the state allocation algorithm, using available time series
data, and iv) simplifies the process of PSA, an essential
part of CEAs, avoiding the necessity of applying addi-
tional sampling techniques such as Monte Carlo or Latin
Hypercube Sampling once the model output is available.
The paper is structured as follows: Firstly, we describe
compartmental models in widespread use for CEAs on
interventions against infectious diseases. Secondly, we
introduce our contribution of the dynamic Bayesian MM.
Thirdly, we compare the performance of an ODE sys-
tem including fixed values on the model parameters and
an ODE system in a Bayesian framework to our method-
ology, using a case study of a chronic sexually trans-
mitted infection. To contrast the three methodologies in
practice, we compare the natural history of disease fol-
lowing calibration, and conduct CEAs including PSA,
comparing a screening strategy to a hypothetical vac-
cine. Finally, we discuss advantages and disadvantages of
ODE-based methodology in comparison to the dynamic
Bayesian MM.
Methods
Compartmental models consist of a set S of mutually
exclusive and exhaustive states describing disease infec-
tion and progression. We indicate the elements of S as
s = 1, . . . , S. Members of a “virtual” population move
across the states over a pre-specified time horizon.
Figure 1 shows an example of a compartmental model
incorporating the natural disease history of a chronic sex-
ually transmitted infection (STI) with S = 5 states which
is deemed similar to HIV [38]. The assumptions encoded
by this structure are that the whole population initially is
in the state Susceptible (indexed by s = 1), from which a
proportion can move to the state Infected (s = 2). Follow-
ing this, people move to an Asymptomatic state (s = 3). A
progression to the stateMorbid (s = 4) induces the devel-
opment of disease symptoms. The state Dead (s = 5) can
be reached from any state; people die due to any cause
or as a consequence of being in the state Morbid. Com-
pared to the average population, the latter have a higher
risk of death. A transition from one state to another is
defined according to transition parameters [39]. They are
indicated as φr,s, where r, s ∈ S represent the original
and target state, respectively. People proliferate at a rate χ ,
resulting in a replenishment of the pool of susceptibles at
risk of contracting the infection.
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Fig. 1Model structure of a hypothetical chronic sexually transmitted infection. The arrows represent the possible transitions. These are governed by
the parameters φr,s with indices r, s ∈ S representing origin and target states, respectively. The replenishment of the pool of susceptibles by
newborns proceeds at a rate χ
Compartmental models may differ in two characteris-
tics. The first is the specification of time. The most real-
istic option is to allow transitions among the states at any
point in time t > 0; this is a so-called “continuous-time
approach”. Alternatively, it is possible to assume that tran-
sitions occur in discrete time where only one transition is
possible within a pre-defined time interval It =[ t, t + κ),
where κ determines the corresponding interval width,
commonly referred to as cycle. Depending on the medi-
cal context, κ can be specified in terms of daily, weekly,
monthly or yearly cycles. The second difference concerns
the way in which population dynamics are considered:
models including a force of infection which accounts for
changes in prevalence are referred to as dynamic, while
those that include a fixed force of infection and thus
ignore the effects of herd immunity are termed static.
In addition, different approaches to model parameter
specification exist, which may have major impact on the
outcome of health economic evaluations. Depending on
the methodology used, the induced computational effort
might not allow the inclusion of probability distributions
on all model parameters. In that case, the model param-
eters are fixed values. Commonly, these are estimated
through a relevant summary, e.g. mean, median or mode,
obtained from available data. The point estimate is then
used as a plug-in for the corresponding parameter. In
contrast, if whole distributions of values are assigned,
parameter uncertainty is propagated through the infec-
tion progression. While frequentist versions of this strat-
egy exist (e.g. based on bootstrap), this type of modelling
is most naturally handled within a Bayesian paradigm.
Ordinary differential equation models
ODE systems model the rate of change in the number
of people within a given state in continuous time; thus,
the corresponding parameters are transition rates and we
denote them as ρr,s(t), with r, s ∈ S representing again the
origin and target states, respectively. In principle, transi-
tion rates can depend on t, but do not necessarily have to.
The number of people transitioning in each state at t is
multiplied by the corresponding transition rates to obtain
the inflow and outflow to and from a state. The difference
between the number of people entering and leaving a state
corresponds to the derivative of the number of those in
the respective state.
Back to our example, we define the vector n(t) =
(n1(t), . . . , nS(t))′, where ns(t) is the number of people in
state s at time t. The corresponding ODE system is given
by the set of equations
dn1(t)
dt = χ [n1(t) + n2(t)+n3(t)+n4(t)]−ρ1,2(t)n1(t)
− ρ1,5n1(t)
dn2(t)
dt = ρ1,2(t)n1(t) − ρ2,3n2(t) − ρ2,5n2(t)
dn3(t)
dt = ρ2,3n2(t) − ρ3,4n3(t) − ρ3,5n3(t) (1)
dn4(t)
dt = ρ3,4n3(t) − ρ4,5n4(t)
dn5(t)
dt = ρ1,5n1(t) + ρ2,5n2(t) + ρ3,5n3(t)+ρ4,5n4(t).
The rate of change in the number of people in each state
at each point in time t is subject to population dynamics
and exposure to sources of infection. The transition to the
state of infection is determined by the dynamic force of
infection of the pathogen, indicated by ρ1,2(t) in (1). This
is a function of the probability of pathogen transmission,
partner acquisition rates and prevalence.
If each model parameter is assigned a fixed value,
parameter uncertainty is not accounted for. Scenario anal-
yses are often performed, for example by estimating the
parameters through summary statistics at the extremes of
the corresponding parameter distribution (e.g. lower or
upper quantiles, minima or maxima). As mentioned ear-
lier, this is not equivalent to the application of a full PSA.
Theoretically, it is possible to incorporate a proba-
bility distribution for each parameter of an ODE-based
model, for example in a Bayesian context. The uncertainty
is then propagated through the estimation procedure,
which again generates a full distribution of outcomes.
This type of model can be analysed using for instance
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software based on Markov Chain Monte Carlo (MCMC)
algorithms such as WinBUGS [40] or Stan [41], a very
promising tool, which in general performs extremely
well with relatively complex systems. Both include ODE
solvers and can be linked to the statistical programming
language R.
In realistic problems including a large number of states
and complex structures, assigning a suitable distribution
to all model parameters in ODE systems may be imprac-
tical since the model needs to be run for a large number
of simulations to ensure convergence of each parame-
ter and thus the ODEs have to be solved repeatedly for
each parameter combination. The increase in the compu-
tational time is induced by the length of the observation
time horizon, the amount of parameters, the complexity
of contacts, and most importantly by the number of states
which increases the number of differential equations.
Consequently, complex ODE-based models which incor-
porate distributions on all parameters are rare excep-
tions in the literature on infectious disease transmission
modelling [42].
Discrete-time Markov models
The main characteristic of MMs is the Markov assump-
tion which implies that the transition to a future state is
exclusively conditional on the current state or on a limited
set of previous states, but not on the full trajectory. How-
ever, the Markov assumption can be relaxed by account-
ing for covariates (e.g. age and sex) or for time-specific
prevalence and population dynamics in the transition
parameters.
ODE systems and MMs differ in the way they describe
the process of transitions. As suggested earlier, in the
former, the rates of change are calculated dynamically
through differentiation, while in the latter, the transitions
are described by a static Markov process (a category of a
stochastic process). As for ODE-based models, MMs can
be implemented for continuous time.
However, the vast majority of MMs in the health eco-
nomic literature is based on a discrete-time approach [43].
In this case, members of the population move across the
states according to a set of transition probabilities only
once per time interval (termed “Markov cycle”). These
probabilities can be arranged in a matrix  = (πr,s
)
,
whose elements represent the transition probabilities for
movements from an original state r to a target state s.
For the model structure of Fig. 1, the transition proba-
bility matrix is defined as
 =
⎛
⎜
⎜
⎜
⎜
⎝
π1,1 π1,2 0 0 π1,5
0 π2,2 π2,3 0 π2,5
0 0 π3,3 π3,4 π3,5
0 0 0 π4,4 π4,5
0 0 0 0 1
⎞
⎟
⎟
⎟
⎟
⎠
,
implying that, for example, a susceptible either acquires
the infection (with probability π1,2), dies (with proba-
bility π1,5), or remains susceptible, which occurs with
probability π1,1 = 1 − π1,2 − π1,5.
If we define the vector nt = (n1t , . . . , nSt)′, where nst
is the number of people in state s and at each time inter-
val It , then transitions across the states from one time
interval to the next are calculated as
nt+1 = nt . (2)
MMs are relatively straightforward to implement and
are commonly used to model the progression of non-
communicable conditions such as cardiovascular disease
and cancer. Therefore, they are established in the health
economic literature and well-known to clinicians and
decision makers. However, the process of pathogen trans-
mission is not estimated correctly using standard MMs. A
transition of susceptibles to the state of infection is com-
monly represented by a static transition parameter which
does not consider changes in the population prevalence
over time. These especially occur after the introduction of
a preventive intervention such as vaccination into a fully
susceptible population.
The predictions of static MMs on population preva-
lence are commonly incorrect (although notable excep-
tions include scenarios with very low vaccine coverage or
pathogens that cannot be transmitted between humans,
e.g. tetanus). In the worst case, the whole model outcome
on infection prevalence and the related CEA can be incor-
rect, e.g. because of the impact of an unrecognised shift
in the age of infection of childhood diseases. Some child-
hood diseases are relatively harmless in young children
but prone to lead to serious health issues in adults. Incor-
rect predictions of static MMs on population health and
induced costs, e.g. through hospitalisation and treatment,
can have dire consequences [29].
As for ODE-based models, a dynamic force of infection
could be incorporated into the transition probabilities to
account for the effects of herd immunity. However, to the
best of our knowledge, dynamic Markov models are not
commonly used in the health economics literature.
Dynamic Bayesian Markov models
To overcome the limitations discussed above and with
a view to extending the modelling framework for health
economic evaluation of interventions in infectious dis-
ease, our main idea is to add a force of infection which
depends on population dynamics and prevalence into a
MM setting. As a consequence, the transition probabilities
from the state Susceptible to the state Infected are directly
defined by the dynamic force of infection. Specifically, we
set up our model so that the force of infection is calcu-
lated separately within each cycle of the state allocation
algorithm corresponding to (2) as a function of
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• the probability of pathogen transmission per contact,
which we indicate as β ;
• the rate of contacts between susceptible and
infectious members of the population ω; and
• the time-dependent pathogen prevalence
ψt = ItNt ,
where It represents the number of people in the state
of infection and, assuming that state S indicates
death,
Nt =
S−1∑
s=1
nst
is the number of those alive at time interval It .
The force of infection is recalculated at each Markov
cycle as
λt = βωψt . (3)
Since ω is a rate, (3) also results in a transition rate.
Assuming that λt remains constant within each time inter-
val, the corresponding time-dependent transition proba-
bility for the discrete-time MM is estimated as
π1,2,t = 1 − exp−λt . (4)
We acknowledge that the estimation of the force of
infection may be only approximate, due to the competing
risk of death and the assumption of uniformity within the
intervals It . This assumption is not likely to hold if the
disease is characterised by very fast transmission, or when
events associated with the infection are likely to occur in
short periods of time. In these cases, it is perhaps advisable
to reduce the length κ of the cycles and the duration of
the follow-up, to avoid unrealistic estimates for the num-
ber of subjects in the states per cycle. For example, for
yearly cycle length, immediate death following infection
would be delayed by up to one year. These delays would
then accumulate through the whole model and introduce
a more substantial bias at later follow-up.
However, a likelihood function for interval censored
data could be estimated to account for competing risks
as shown in [44, 45] for an independent inspection pro-
cess (IPP) model; this model allows for future movements
to be conditional on the history of the data. In Lemma 1,
Hudgens et al. [44] present this likelihood under the
assumption that only one event can occur per cycle. As an
alternative to (4), this likelihood could be derived for the
cumulative distribution function of an exponential model.
Moreover, competing risks could be considered through
the Kolmogorov forward equations. This alternative
approach would allow for the possibility that more than
one event could occur per cycle; for instance, one could
acquire the infection followed by death within the same
cycle. In order to move from the state Susceptible to
Infected, one would have to take into account that the
infection was acquired and death did not occur within the
remainder of that cycle. For the exponential distribution,
the corresponding Kolmogorov forward equation to esti-
mate the transition probability of moving between the two
states was derived as
π1,2,t = exp−ρ1,5(t)
(
1 − exp−λt ) , (5)
accounting for ρ1,5(t), the transition rate of moving from
the state Susceptible to Death. Replacing (4) by (5), the
accuracy of the approximation of π1,2,t could improve.
Notice, however, that in the case study presented in
Section “Case study”, the probability of death is very low
in susceptibles (who are by definition in good health and
of young age) and therefore this additional complication
in the estimation of the transition probability is not nec-
essary. The results of the corresponding discrete- and
continuous-time models are comparable; the approxima-
tion in (4) is therefore deemed sufficient.
The transition probability π1,2,t approximated by (4) is
multiplied by the proportion of the population in the state
Susceptible to provide an estimation of the contingent
of movements to the state Infected, effectively including
dynamic, time-dependent changes in prevalence in the
corresponding transitions.
The computational effort is reduced by fitting models
that do not involve complex ODEs, while still allowing for
mixing patterns within the population. Another potential
advantage of the dynamicMM framework is that it is fairly
simple to incorporate suitable probability distributions on
all model parameters, even if the model is complex with
an extremely large number of parameters and states. In
contrast, the related computational effort in a compara-
ble ODE-based model would be extremely high due to
i) numerical integration, e.g. through the Runge-Kutta
solver [46]; ii) considerably smaller step sizes of ODE
solvers when compared to the cycle length of discrete-
time models; and iii) accounting for competing risks
in the transition rates as elaborated above. The model
can be easily extended to include a high number of age
cohorts for infectious diseases with age-specific preva-
lence such as HPV; we present this application includ-
ing 24 age cohorts at manageable computational effort
elsewhere [36].
Accounting for parameter uncertainty is particularly
relevant because, for obvious ethical and practical rea-
sons, it is invariably difficult (if possible at all) to obtain
and use experimental evidence to inform the pathogen
transmission probability β and the active contact rate
ω — arguably the crucial parameters. Often observational
studies or expert opinions are the only available informa-
tion with the consequence that large uncertainty remains
over the most likely range, let alone the “true” value of
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the parameters. A Bayesian approach may provide great
benefit in allowing this uncertainty to be fully propagated
and perhaps in integrating different sources of evidence
(e.g. using evidence synthesis [39]); this indeed has been
advocated for MMs in the health economics literature
[9, 39, 47]. In [48], β is assigned a Uniform distribu-
tion in the interval [0;1], which essentially amounts to
allowing any value (between 0 and 100%) as equally pos-
sible. We have performed extensive sensitivity analysis
to this parameter in the HPV model and found that the
prevalence outcome was highly sensitive to this parameter
(results not published).
In a Bayesian dynamic MM setting, it is possible to
assign prior distributions to the parameters (β ,ω) to rep-
resent the state of science — if data are available, these are
updated into posterior distributions although it is possi-
ble to still propagate uncertainty in the priors even when
no data on pathogen transmission or active contacts are
observed. In addition, the quantityψt is estimated for each
cycle as a function of transition probabilities, which can
also be modelled using suitable distributions. This mod-
elling process induces a probability distribution on ψt and
a fortiori also on λt , which is defined as a function of
the three random parameters (β ,ω,ψt). Thus, the corre-
sponding transition probabilities π1,2,t are modelled prob-
abilistically, meaning that uncertainty in the population
dynamics is propagated through the economic model.
If β and ω are varied simultaneously and difficult to
inform directly using empirical evidence, the force of
infection may be subject to issues of non-identifiability,
i.e. it is possible that it cannot be distinguished to what
extend differences in the corresponding outcome on the
number of subjects in the state Infected are induced by
which parameter. Individuals become infected as a con-
sequence of meeting an infected subject (determined by
β) once or several times (determined by ω). However,
we note here that we are mainly interested in the over-
all number of subjects in the state Infected, irrespective
of the number of contacts that are necessary to result in
an infection. Therefore, in the economy of our modelling
framework, it is less important if changes in the number of
subjects in the state Infected are induced by β or ω. Never-
theless, we do acknowledge this issue and suggest careful
consideration of the prior assumptions when investigating
sensitivity of the results.
Another crucial aspect in infectious disease modelling
(and more generally in statistical analysis) is that of cali-
bration of the model output [49, 50]. The Bayesian frame-
work enables the calibration of the numbers of people
in the states directly in the state allocation algorithm,
using available time series data for a specific time frame
of follow-up. The corresponding details are explained
in “Model parameters and related distributions” section
and Appendix 2.
The BMM is generalizeable to any infectious dis-
ease which is transmitted between humans and where
interventions (e.g. quarantine, vaccination, antibiotic or
antiviral treatment) are available to reduce infection
prevalence. It is especially suitable to include an extremely
high number of states, model parameters with suitable
distributions, and age cohorts as shown in [36].
To estimate the efficacy and cost-effectiveness of
an intervention, only dynamic models predict realistic
outcome and account for herd immunity in case of vac-
cination. Yet, any kind of intervention which reduces
prevalence has a protective impact on susceptibles who do
not directly receive it; this can be considered in the BMM.
Finally and specifically for the purpose of economic
evaluation, the dynamic BMMhas the advantage that PSA
can be performed “for free”, once the model output is pro-
duced. In a Bayesian framework, the MCMC simulations
for all the model parameters can be combined to obtain
a full characterisation of the uncertainty in the decision-
making process. This can be post-processed (e.g. using
the R package BCEA [51]) to produce relevant summaries
such as the cost-effectiveness plane, the cost-effectiveness
acceptability curve and the analysis of the value of infor-
mation (see “Cost-effectiveness analysis” section).
Our approach to a dynamic BMM provides PSA sam-
ples directly as part of the probabilistic model output.
Therefore, in addition to simpler probabilistic sensitiv-
ity analysis (e.g. based on CEACs), the BMM enables the
conduct of extensive Value of Information (VoI) analy-
sis, which can be used to prioritise further research on
key model inputs, currently driving uncertainty in the
decision making process. For example, recent methods
have been developed for fast computation of both the
Expected Value of Partial Perfect Information (EVPPI)
and the Expected Value of Sample Information (EVSI)
[52–54] that use simulations from the model parameters
obtained directly during the process of PSA. The BMM
conforms with this structure and would thus be suitable
for VoI analysis based on these methods, without the need
to divorce the transmission model from the economic
evaluation, as often happens in current practice.
Case study
We consider again the fictional chronic STI described
above and compare the dynamic Bayesian MM to both
a deterministic and a Bayesian ODE system. We denote
the three models as BMM, dODE and BODE, respec-
tively. We evaluate whether our BMM produces results
that are in line with the “gold standard” of the BODE. In
the three models, we distinguish between sexes as well as
high- and low-risk sexual behaviour. The duration of the
follow-up is set at 100 years, with a yearly Markov cycle
length. We consider a population size of 1,000,000 and
initially assume that 600 people are infected, whereas the
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remainder are susceptible. Males amount to 50% and the
high-risk group to 20% of the population; the sex ratio in
the two risk groups is constant. The proportion of infected
people in both sexes and risk groups is identical. We
account for sex-specific differences in sexual behaviour,
assuming higher partner acquisition rates in males. The
population size changes due to births and deaths. We
conduct our analysis for two competing health-care inter-
ventions. We assume that in the status-quo, screening
takes place at intervals of five years at a pre-defined rate
to enable an early detection of the STI. For simplicity, we
assume that under the vaccination scenario no screening
takes place. We assume that the vaccine is only effective
before initial STI infection; thus, susceptibles are vacci-
nated at a specified vaccine uptake rate at intervals of five
years. Following STI diagnosis, treatment is provided in
both interventions.
In the dODE and BODE, the force of infection (transi-
tion rate from the state Susceptible to the state Infected)
shown in (3) has to be adjusted to account for the covari-
ates sex and behaviour with respect to infection preva-
lence. In the BMM, the sex- and behavioural-specific
transition probability is estimated by transforming this
adjusted transition rate according to (4). For simplicity, we
exclusively account for randommixing. Further details are
given in Appendix 1.
Model parameters and related distributions
In addition to the probability of STI transmission β and
the partner acquisition rates ωvb, the model contains
a variety of parameters such as those determining the
screening and vaccine coverage, the unit costs of STI
diagnostics and treatment and the health utilities, which
are relevant in context of the cost-effectiveness analy-
sis. We assign informative priors to transition param-
eters and costs (defined in monetary units of £) and
utilities. We specify the distributional assumptions so
that the outputs of the health economic evaluation
are within reasonable ranges. We assign informative or
minimally-informative priors to the remaining parame-
ters and update these through simulated individual-level
and aggregate data into the corresponding posteriors.
Using simulated data is reasonable since the case study
is fictional. For example, we pretend that data on part-
ner acquisition rates ωvb are available from a large data
registry. To infer ωvb, we update informative Gamma
priors into the corresponding posteriors through Poisson-
Gamma models. Beta-Binomial models are used to infer
probabilities (e.g. the vaccine coverage α and efficacy γ ,
which are informed by data). We assume to have access
to vaccination data of 500 individuals of whom 450 have
received the vaccine. In addition, we assume to have the
information that in 450 out of 500 people who received
the vaccine, it was effective.
Table 1 shows an overview of the model parameters
θ = {ωvb,χ ,β ,πr,s, τ , ξ , γ , σ , c,us}. The means and 95%
credible intervals are displayed for the BMM (the val-
ues in the BODE are comparable) and rounded to two
decimal places. However, the 95% CI of the parameter
χ is in fact defined as [0.009420;0.010596]. Since the
BMM is based on a discrete-time approach, the cor-
responding transition probabilities are modelled using
Beta distributions. In contrast, the transition rates of the
continuous-time BODE are modelled using Gamma dis-
tributions. The transition probabilities for movements
from the states Susceptible, Infected and Asymptomatic to
Dead are assumed as identical; thus, only π1,5 is shown.
Depending on the medical context, correlations
between posterior distributions are possible and infor-
mative priors can result in quite different posterior
distributions, if they are influenced by the updating
process of other priors. This might occur in parameters
which are not independent, for example transition param-
eters to certain states calculated by means of hierarchical
models. In this respect, for example the transition prob-
ability to the state Dead might be dependent on one to a
less severe state such as Morbid. Potential correlation is
automatically accounted for in the PSA.
The dODE is calibrated through a frequentist proba-
bilistic calibration approach [50, 55], whereas the BODE
and BMM are calibrated through Bayesian calibration
approaches [56, 57]. The first involves the calculation of
goodness-of-fit statistics. The advantage of the latter is
that the model parameters can be inferred by fitting the
models to data directly (in one step). Simulated time series
data on the number of high-risk people in the states Sus-
ceptible, Infected, Asymptomatic and Morbid in the first
five years of follow-up are used for calibration. A short
observation time horizon of only a couple of years (five
years in this case) is common in available time series data.
These data are simulated by running the dODE under
the status quo for a follow-up period of five years; the
input parameter values are informed through the means
of the parameters of the BODE. In many infectious dis-
eases, only data on the number of infected individuals are
available. The model code can easily be adapted to only
calibrate the outcome on one of the states since every
state is calibrated separately. Further details are given in
Appendix 2.
The dODE is estimated using a combination of the
R packages EpiModel [58] and deSolve [59]. As for
the BMM and BODE, we estimate the model parameters
using a MCMC procedure; we run two chains with a total
of 1,000 simulations after convergence. In this setting,
convergence is sufficiently achieved with a Potential Scale
Reduction Rˆ < 1.1 in all model parameters [49], and there
are no issues with autocorrelation. We fit the BODE in
WinBUGS through the ODE solver interface WBDiff [60].
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Table 1 Overview of the informative priors and the models used for updating informative and minimally-informative priors
Parameter Description Distribution/model BMM Distribution/model BODE Mean 2.5/97.5% percentiles
ωMH Partner acquisition rate (high-risk
males)
Poisson-Gamma model Equivalent to BMM 9.10 [8.77;9.29]
ωML Partner acquisition rate (low-risk
males)
Poisson-Gamma model Equivalent to BMM 2.98 [2.82;3.12]
ωFH Partner acquisition rate (high-risk
females)
Poisson-Gamma model Equivalent to BMM 9.00 [8.71;9.26]
ωFL Partner acquisition rate (low-risk
females)
Poisson-Gamma model Equivalent to BMM 1.96 [1.86;2.09]
χ Proliferation parameter Gamma(1111.1,111111.1) Gamma(1111.1,111111.1) 0.01 [0.01;0.01]
β STI transmission probability per
partnership
Beta-Binomial model Equivalent to BMM 0.16 [0.15;0.16]
π2,3 Transition parameter from state 2 to
state 3
Beta(5119.2, 1279.8) Gamma(25600,32000) 0.80 [0.79;0.81]
π3,4 Transition parameter from state 3 to
state 4
Beta(1842.66, 18631.34) Gamma(2025,22500) 0.09 [0.09;0.09]
π4,5 Transition parameter from state 4 to
state 5
Beta(1535.96, 36863.04) Gamma(1600,40000) 0.04 [0.04;0.04]
π1,5 Transition parameter from state 1 to
state 5
Beta(156.171, 312186.6) Gamma(156.25,312500) <0.01 [<0.01;<0.01]
η Probability of STI diagnosis Beta-Binomial model Equivalent to BMM 0.90 [0.88;0.92]
σ Screening probability Beta-Binomial model Equivalent to BMM 0.90 [0.87;0.92]
α Vaccine coverage parameter Beta-Binomial model Equivalent to BMM 0.90 [0.87;0.92]
γ Vaccine efficacy parameter Beta-Binomial model Equivalent to BMM 0.90 [0.87;0.92]
cscreen Unit cost of screening in £ Lognormal(2.996, 0.693) Equivalent to BMM 25.39 [5.19;77.53]
cvac Unit cost of vaccination in £ Lognormal(5.011, 0.01) Equivalent to BMM 150.02 [147.14;152.98]
ctest Unit cost of STI test in £ Lognormal(2.996, 0.03) Equivalent to BMM 20.01 [18.83;21.19]
cblood Unit cost of blood test in £ Lognormal(3.401, 0.03) Equivalent to BMM 30 [28.26;31.79]
ctreat Unit cost of treatment in £ Lognormal(8.517, 0.015) Equivalent to BMM 4999.78 [4853.56;5149.24]
cdis Unit cost of disease treatment in £ Lognormal(9.210, 0.01) Equivalent to BMM 9999.95 [9802.97;10198.10]
cgp Unit cost of visit to general practi-
tioner in £
Lognormal(3.912, 0.02) Equivalent to BMM 50.01 [48.08;52.01]
u2 Health utility of infected (min=0,
max=1)
Beta(1469.3, 629.7) Equivalent to BMM 0.70 [0.68;0.72]
u3 Health utility of asymptomatic
(min=0, max=1)
Beta(1439.4, 959.6) Equivalent to BMM 0.60 [0.58;0.62]
u4 Health utility of morbid (min=0,
max=1)
Beta(629.7, 1469.3) Equivalent to BMM 0.30 [0.28;0.32]
The values are fictional and were chosen so as to produce most realistic prevalence outcome and cost-effectiveness results
The BMM is estimated using WinBUGS and JAGS [61],
an alternative, established software to performGibbs sam-
pling, in order to compare computational efficiency.
The models are run on a Dell Latitude E6320 (Intel
Core i5-2520M, 2x4GB DDR3 RAM, 500GB SATA HDD
(2.5", 7200rpm)). The computation times are 4,480.19 sec-
onds (around 1 hour 15 minutes) and 6,587.67 seconds
(around 1 hour 50 minutes) for the dODE and BODE,
respectively. Interestingly, the BMM runs much faster in
JAGS (149.81 seconds) than in WinBUGS (449.42 sec-
onds). This difference is perhaps due to the way in
which the two programmes handle logical nodes, which
are instrumental to defining the state allocation algo-
rithm (see (2)). All run times include model calibration
which considerably increases the computational effort in
the ODE systems, but not for the BMM. The relevant
model codes are presented as Additional file 1 BODE.txt,
BMM(WinBUGS).txt and BMM(JAGS).txt.
As discussed in “Dynamic Bayesian Markov models”
section, identifiability could also become an issue when
the posteriors of β and ω are multimodal, which may
happen if certain parameter combinations are more likely
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to favour the data on partner acquisition rates and STI
transmission probabilities. As a consequence, the sam-
pling algorithm could get stuck in one of the local modes,
resulting in biased summary statistics. We generate dif-
ferent initial values for each Markov chain to reduce the
risk that parts of the posterior distribution are not vis-
ited when producing the relevant samples. In addition,
we evaluate whether the two chains show proper mixing
through trace plots.
Results
Natural history of disease
Figure 2 shows the outcome on the natural history of
the fictional chronic STI following calibration. Only the
results on high-risk females are displayed; those on high-
risk males are comparable. The BMM produces results
which are comparable to the “gold standard” of the BODE.
The model outcome on the states Susceptible and Mor-
bid of the BMM and BODE is basically identical, whereas
the outcome of the BODE shows slightly higher esti-
mates on the number of infected and asymptomatic high-
risk females. The outcome on the number of susceptible
and morbid high-risk females is higher in the dODE;
in contrast, the outcome on those in the states Infected
and Asymptomatic is lower when compared to the two
Bayesian models. The ranges of the 95% credible intervals
of the BODE and BMM are similar, showing wider ranges
in the BMM. The 97.5% quantiles of the scenario analysis
of the dODE are lower than the upper bounds of the 95%
CIs in the states Infected and Asymptomatic and higher in
the states Susceptible andMorbid, whereas the 2.5% quan-
tiles are considerably lower than the lower bounds of the
CIs (apart from the state Susceptible).
Cost-effectiveness analysis
We denote the unit costs and utilities as csti and us, with
indices s, t and i representing states s ∈ {1, . . . , S}, obser-
vation time points t and interventions i = 1 (status quo)
and i = 2 (vaccination). We assume decreasing utility val-
ues for more severe states. Costs are induced by screening,
vaccination, a visit at the general practitioner and diag-
nostic tests. Following a positive STI diagnosis, further
diagnostic tests and treatment are necessary. For all these
quantities, the distributional assumptions are presented in
Table 1.
The overall costs per intervention are calculated as
Ci =
T∑
t=1
S∑
s=1
csinsti
(1 + δ)t−1 ,
where nsti are the number of people in state s at time
t when intervention i is applied and δ is the yearly dis-
count rate. In both the continuous- and discrete-time
approaches, the model output on the natural history of
disease infection and progression is evaluated at pre-
specified time points t ∈ {1, . . . ,T}, where T represents
the end of follow-up. We discount both costs and ben-
efits at a fixed yearly rate δ = 0.03, following ISPOR
recommendations [62]. Similarly, the overall utilities are
computed as
Ui =
T∑
t=1
S∑
s=1
usnsti
(1 + δ)t−1 .
Overall costs and utilities define the monetary net ben-
efit NBi(θ) = kUi − Ci. The economic evaluation is
performed by calculating suitable summaries such as the
increment in mean cost c = C2 − C1 and the increment
in mean effectiveness e = U2 −U1 between vaccination
and the status-quo, or the incremental cost-effectiveness
ratio
ICER = E[c]E[e] .
In the BMM and BODE, these quantities are estimated
directly as function of the parameters, while in the dODE,
we conduct a scenario analysis including the 2.5% and
97.5% quantiles of the ICER to evaluate the range of “plau-
sible” results. A cut-off point of a willingness-to-pay k
of approximately £20,000 – £30,000 per QALY gained,
adopted by NICE [63], is used as the benchmark of value
for money.
As for PSA, it is usually based on: (i) the analysis of
the cost-effectiveness plane, depicting the joint probability
distribution of (e,c); (ii) the cost-effectiveness accept-
ability curve CEAC = Pr(ke − c > 0), which shows
the probability that the reference intervention is cost-
effective as a function of the willingness to pay k; and (iii)
the expected value of “perfect” information
EVPI = Eθ
[
max
i
NBi (θ)
]
− max
i
Eθ [NBi (θ)] ,
which quantifies the maximum amount of money that
the decision-maker should be willing to invest (e.g. in a
new study) in order to resolve parameter uncertainty and
thus make a “better” decision. The Bayesian models can
perform these analyses in a straightforward way, since
these quantities are all functions of the model parame-
ters and thus a full posterior distribution can be directly
obtained.
The ICER of the dODE results in £ 7,203.416, rang-
ing between £ 2,592.44 and £ 469,906 in the scenario
analysis at the 2.5% and 97.5% quantiles. The ICERs
of the Bayesian models are comparable to the dODE,
resulting in £ 6,054.82 and £ 6,287.62 in the BODE and
BMM, respectively.
Figure 3 displays the cost-effectiveness plane. Each point
of the MCMC simulation lies within the grey sustainabil-
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Fig. 2 Calibration results on the number of high-risk females in the states following a systematic probabilistic calibration approach. The results of the
Bayesian models are similar, with a slightly higher number of high-risk females in the states Infected and Asymptomatic estimated by the Bayesian
ODE-based model. In contrast, the deterministic ODE-based model results in a lower estimate on the number of high-risk females in the states
Infected and Asymptomatic; however, the outcome on the stateMorbid is reversed
ity area, indicating that STI vaccination is cost-effective
at a threshold of £ 25,000 when compared to STI screen-
ing. STI vaccination is deemed to be both more expensive
and more effective than STI screening since all points are
located in the upper right quadrant of the graph. The cor-
responding ICERs of the BMM and BODE are displayed
as red and blue dots, respectively.
Figure 4 shows the results of the CEACs and the pop-
ulation EVPIs of the two Bayesian models. The amount
of uncertainty in the BMM is slightly larger than in the
BODE; however, 80% cost-effectiveness is clearly reached
at the break-even points of the ICERs of both models.
The population EVPI of the BMMat around £ 500,000,000
is higher than in the BODE, where it reaches a value of
around £ 400,000,000. The higher EVPI value of the BMM
is a consequence of the slightly larger amount of uncer-
tainty. Thus, the value of additional research is higher in
the BMM.
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Fig. 3 Cost-effectiveness planes of the Bayesian ODE system and
Bayesian Markov model. The cost-effectiveness plane indicates that
vaccination is both more expensive and more effective than the
status quo. All points lie within the sustainability area of
cost-effectiveness. The ICERs of £ 6,054.82 (blue dot, BODE) and
£ 6,287.62 (red dot, BMM) indicate cost-effectiveness of STI
vaccination in comparison to STI screening at a threshold of £ 25,000
Discussion
In this paper we have presented a comparison of
modelling methods for the economic evaluation of
interventions in infectious disease. We acknowledge that
ODE-based models have several advantages and consider
the Bayesian ODE structure as ideal to combine trans-
mission modelling with economic evaluation. However,
including a large number of states and probability distri-
butions on a high number of model parameters induces
computational issues, which effectively acts as a barrier
to the application of complex economic modelling in this
area. This possibly explains why the extensive application
of PSA is limited in comparison to many other disease
areas, in health economics.
From the technical point of view, constructing a BMM
is relatively simple and does not require the use of spe-
cialised software — in fact our analysis has been per-
formed using R and the Gibbs samplers WinBUGS and
JAGS, which are often used by statisticians and health
economic modellers and thus by reviewers and advis-
ers for health technology assessment agencies. This may
again facilitate the communication of complex modelling
assumptions and thus the economic assessment of com-
plex interventions such as those based on vaccination
programmes.
We of course acknowledge that the run time of the
BODE could be reduced, for example using optimised
code implemented in C. This is also true of the BMM,
which could be coded using C directly. We note, however
Fig. 4 Cost-effectiveness acceptability curves and expected value of information of the Bayesian ODE system and Bayesian Markov model. The
results of the BMM are displayed in grey, whereas those of the BODE are shown in black. The amount of parameter uncertainty is higher in the BMM.
The CEACs in the left panel reach values of 80% at a willingness-to-pay corresponding to the ICERs. The EVPIs for the whole population at around
£ 500,000,000 and £ 400,000,000 in the BMM and BODE, respectively, are shown in the right panel
Haeussler et al. BMCMedical ResearchMethodology  (2018) 18:82 Page 13 of 16
that a Bayesian implementation of an ODE system is more
computationally intensive than the corresponding deter-
ministic version, due to the MCMC component needed
to obtain the estimate for the posterior distributions of
the relevant parameters. In addition, our proposal aims
at giving a general framework: it is possible that in spe-
cific cases modellers will be able to write highly optimised
code that reduces the computational time. In general
terms, however, our experience suggests that many mod-
ellers working in health economic evaluation would not be
necessarily familiar with specialised code (e.g. C).
Moreover, it is important that the code used to provide
the evaluation of the transmission model is made avail-
able to reviewers (e.g. NICE appraisal committee), among
whom a language such as WinBUGS is familiar, but other,
more advanced programming languages are not. Finally,
the possibility of estimating the transmission model and
embedding in the economic model has the potential to
improve the overall process (because the modellers devel-
oping the latter would be equipped with the technical
expertise to develop the former too).
In addition to language, a more crucial point with
respect to computational efficacy is given by the choice
of the MCMC sampler. An alternative to a Gibbs sampler
would for example be Hamiltonian Monte Carlo (HMC),
which is a more efficient algorithm. Random walks are
avoided using HMC since the gradient information is
used. As a consequence, the algorithm is able to sample
more efficiently from regions of high probability [64].
Conclusion
Our proposal of a dynamic Bayesian Markov model can
be seen as an effective compromise between the ideal
ODE-based models including suitable distributions on all
model parameters and simpler structures of MMs that fail
to account for time-dependent changes in prevalence and
the effects of herd immunity. While providing a sparser
temporal resolution in the way in which transmission is
modelled, our methodology has the advantage of account-
ing for parameter uncertainty. This in turn means that
standard economic analysis, including PSA, can be per-
formed in a straightforward way. In addition, Markov
models are a well established tool in health economics,
which may facilitate the translation of the modellers’ work
to the regulators and assessors.
In the fictional example presented in this paper, our
BMM performs just as well as the BODE, with seiz-
able computational savings. Model predictions should
always be calibrated, given time series or prevalence
data are available. Systematic calibration approaches usu-
ally induce a considerably high computational effort. We
could show that including a direct calibration approach in
the Bayesian models, the BMM runs 15 times faster than
the BODE.
Appendix 1
Sex- and behaviour-specific force of infection
In the case study described in “Case study” section, the
force of infection presented in (3) is adjusted to addition-
ally account for sex and behaviour. The indices v, v′ =
(Male, Female) indicate the respective sex and its oppo-
site. For example, a male is represented through the index
M; the index of his female mixing partner is F. The sex-
ual behaviour group is represented through the index
b = (Low, High). In the ODE models, the transition rate
ρv,b,1,2(t) from the state Susceptible to the state Infected
depends on the covariates sex and behaviour. In the BMM,
the sex- and behavioural specific transition probability
πv,b,1,2,t is estimated by transforming ρv,b,1,2(t) according
to (4).
For simplicity, we exclusively account for random mix-
ing; members of the population of sex v randomly select
sexual partners of the opposite sex v′. Because of the
impact of the covariates, the estimation of the overall
prevalence in the sexual partners of sex v′ is a weighted
average of the prevalence in both behaviour groups of
sex v′. We show the corresponding equations for the
continuous-time approach as functions of t; for a discrete-
time approach, these are similar.
The time-specific probability of selecting a partner from
the high-risk group, which we indicate as gv′H(t), depends
on the partner acquisition rates ωv′H and ωv′L as well as on
the population sizes Nv′H(t) and Nv′L(t). The probability
of selecting a partner from the low-risk group is repre-
sented by gv′L(t). The corresponding equations adapted
from [28] only account for two sexual behaviour groups
and are thus extended for sex, to give
gv′H(t) = ωv′HNv′H(t)
ωv′HNv′H(t) + ωv′LNv′L(t)
gv′L(t) = 1 − gv′H(t).
We estimate the sex-, behavioural- and time-specific
force of infection
ρv,b,1,2(t) = βωvbψv′(t),
where
ψv′(t) =
(
gv′H(t)
Iv′H(t)
Nv′H(t)
+ gv′L(t) Iv′L(t)Nv′L(t)
)
is the weighted average of the STI population prevalence,
which is estimated as a function of the probabilities gv′b(t)
of selecting a partner of the opposite sex from one of
the two sexual behaviour groups and the time-, sex- and
behavioural-specific population prevalence Iv′b(t)Nv′b(t) . The
number of infectious people Iv′b(t) is estimated as those
in the state Infected of the respective sex and behaviour
group. In line with (3), the force of infection ρv,b,1,2(t)
is a function of the STI transmission probability per
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partnership β , the partner acquisition rates ωvb, and the
population prevalence ψv′(t).
Appendix 2
Model calibration
The dODE is calibrated through a frequentist probabilis-
tic calibration approach [50, 55]. Suitable distributions are
assigned to the model parameters which are relevant in
terms of natural history of disease. As a next step, sets
of 50,000 parameter combinations are sampled from the
distributions through Monte Carlo sampling. We calcu-
late the sum of squared errors between the outputs of
the model runs (for each parameter set combination) and
simulated data for the first five years of follow-up in four
states as
Q(θ) =
5∑
t=1
4∑
s=1
[
ys(t) − fs (t | θ)
]2 .
The dODE is based on a continuous-time approach;
however, the corresponding output is evaluated at yearly
time intervals t ∈ {1, . . . , 5}. The simulated data on the
number of high-risk people in state s at time t are indi-
cated by ys(t), and fs(t |θ) is the model output on high-risk
people given the input parameter set θ . As a final step, the
set θ corresponding to the output which results in the least
sum of squares is selected; it is displayed in Table 2.
In contrast to the dODE, the BMM and BODE are cal-
ibrated through a Bayesian calibration approach [56, 57].
As described in “Model parameters and related distribu-
tions” section, the advantage is that model parameters can
be inferred by fitting the models to data directly (in one
step).
Table 2 Point estimates of the parameters of the deterministic
ODE-based model obtained through a frequentist probabilistic
calibration approach
Parameter Description Point estimate
ωMH Partner acquisition rate (high-risk males) 8.3515
ωML Partner acquisition rate (low-risk males) 2.4526
ωFH Partner acquisition rate (high-risk females) 8.3836
ωFL Partner acquisition rate (low-risk females) 1.6085
χ Proliferation parameter 0.0100
β STI transmission probability per partnership 0.1639
π2,3 Transition parameter from state 2 to state 3 0.7957
π3,4 Transition parameter from state 3 to state 4 0.0891
π4,5 Transition parameter from state 4 to state 5 0.0232
π1,5 Transition parameter from state 1 to state 5 0.0005
The parameter set θ with the best fit to simulated data minimises the sum of
squared errors
In a Bayesian framework, data can be considered in
several ways. We include simulated data on a selec-
tion of parameters to update the priors into the cor-
responding posteriors. However, this only ensures that
the corresponding parameters are informed by avail-
able evidence. Despite posterior sampling, it could still
be possible that the predicted outcome implied by the
Bayesian models was not comparable to high-quality
data obtained from large data registries. In the BODE,
the output on the number of people in the states over
follow-up corresponds to the solutions of the ODEs.
In the BMM, the output corresponds to the solutions
of the state allocation algorithm, which is given by (2).
In addition to posterior sampling, the outputs of both
models are constantly updated through the simulated
time series data. In fact, this is an additional process of
Bayesian inference, updating the model outcome through
additional data.
The updating takes place by assigning Poisson dis-
tributions to the data; the event rate λ is then rep-
resented by the solutions of the ODEs and the state
allocation algorithm, respectively. The resulting model
outcome is already calibrated, and no further steps such
as the calculation of goodness-of-fit statistics are nec-
essary. The evaluation of the natural history of disease
and the cost-effectiveness analysis including PSA can be
conducted straightforwardly.
Additional file
Additional file 1: The model codes of the BODE (in WinBUGS) and BMM
(WinBUGS and JAGS versions) are provided as additional files BODE.txt,
BMM(WinBUGS).txt and BMM(JAGS).txt. (ZIP 8 kb)
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